Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14602694 | 1.00 | OPRM1 (0.47) | OPRM1OPRL1DPP4SIGMAR1BCHE | |
| SCHEMBL29197407 | 0.92 | OPRM1 (0.52) | OPRM1OPRL1DPP4SIGMAR1BCHE | |
| SCHEMBL31570422 | 0.90 | BCHE (0.41) | OPRM1OPRL1DPP4SIGMAR1BCHE | |
| SCHEMBL23364774 | 0.81 | DPP4 (0.61) | OPRM1OPRL1DPP4SIGMAR1BCHE | |
| SCHEMBL11982107 | 0.77 | BCHE (0.32) | OPRM1OPRL1DPP4BCHECTSL | |
| SCHEMBL11963562 | 0.77 | GBA1 (0.39) | — | |
| SCHEMBL11945826 | 0.77 | OPRM1 (0.55) | OPRM1OPRL1DPP4SIGMAR1BCHE | |
| SCHEMBL16214739 | 0.76 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL1666432 | 0.76 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL1794744 | 0.76 | BCHE (0.40) | OPRM1OPRL1DPP4SIGMAR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808527-B2 | Methods and compositions for treating HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808527-B2 | Methods and compositions for treating HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-11-07 | — | — | US | disclosed |
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | SERPINB1, HPN, PRSS1 | OPRM1 2750/4885OPRL1 4120/4885DPP4 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.